Nasdaq

GE HealthCare achieves MRI portfolio milestone with FDA clearances for next-generation SIGNA MRI technology designed to enhance precision imaging and clinical efficiency

SIGNA Sprint with Freelium, a new 1.5T sealed magnet MRI system, combines a sustainable design with uncompromised image quality, and operational autonomy to expand access to advanced MR, even in ...
Nasdaq

GE HealthCare Introduces Next-Generation SIGNA MRI Technology

(RTTNews) - GE HealthCare (GEHC) announced the submission of its next-generation SIGNA™ MRI technology to the U.S. Food and Drug Administration (FDA) for 510(k) clearance. The new systems are designed ...
Business Wire

GE HealthCare Announces Phase I Results for a First-of-its-Kind Macrocyclic Manganese-Based MRI Contrast Agent

CHALFONT ST GILES, England--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) has today announced the completion of its Phase I clinical development program for a first-of-its-kind manganese-based ...
Business Wire

Imricor Collaborates with GE HealthCare in Interventional Cardiac MRI

MINNEAPOLIS--(BUSINESS WIRE)--Imricor Medical Systems, Inc. (ASX:IMR) Imricor, the global leader in real-time interventional cardiac magnetic resonance (iCMR) ablation products, is pleased to announce ...
Hosted on MSN

GE HealthCare bolsters MRI provision with icometrix acquisition

GE HealthCare has entered an agreement to acquire AI-based brain imaging company icometrix to expand its magnetic resonance (MR) imaging capabilities for neurological disorders. The imaging giant ...
Morningstar

GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation ...

Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to - or even replacing - gadolinium-based MRI agents A manganese-based MRI contrast agent could ...